Nektar Therapeutics buy B. Riley
Start price
09.01.25
/
50%
€1.11
Target price
09.01.26
-
Performance (%)
-47.29%
End price
10.01.26
-
Summary
This prediction is currently being closed. Massive losses of -47.29% have been the result for the BUY prediction by B__Riley. B__Riley has a follow-up prediction for Nektar Therapeutics where he still thinks Nektar Therapeutics is a Buy. B__Riley has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Nektar Therapeutics | - | - | - |
| iShares Core DAX® | 0.721% | 4.566% | 24.333% |
| iShares Nasdaq 100 | -0.413% | 1.884% | 8.848% |
| iShares Nikkei 225® | 3.500% | 7.196% | 24.030% |
| iShares S&P 500 | 0.489% | 2.436% | 6.048% |
Comments by B__Riley for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Ratings data for NKTR provided by MarketBeat
In the thread Trading Nektar Therapeutics
Die von B__Riley gewählte maximale Laufzeit wurde überschritten
Current prediction by B__Riley for Nektar Therapeutics
Stopped prediction by B__Riley for Nektar Therapeutics
Nektar Therapeutics
Start price
Target price
Perf. (%)
€1.09
08.01.25
08.01.25
€3.88
08.01.26
08.01.26
-46.56%
09.01.26
09.01.26
